Back to Search Start Over

False-Positive 18F-FDG PET/CT Imaging

Authors :
Skoura, Evangelia
Ardeshna, Kirit
Halsey, Richard
Wan, Simon
Kayani, Irfan
Source :
Clinical Nuclear Medicine; March 2016, Vol. 41 Issue: 3 pe171-e172, 2p
Publication Year :
2016

Abstract

We report the case of a 45-year-old woman diagnosed with non-Hodgkin lymphoma. Six months after completion of R-CHOP, she relapsed, and 2 cycles of R-ESHAP were given, with a view to allograft transplant. One month later, 18F-FDG PET/CT revealed disease progression. Biopsy of lymph nodes showed reactive changes, without evidence of lymphoma. Rituximab, a monoclonal antibody, is used for treatment of non-Hodgkin lymphoma, but its addition may result in an extensive inflammatory response. It is important to be aware of the potential for false-positive 18F-FDG PET/CT imaging after rituximab therapy. Unexpected findings should be confirmed by biopsy.

Details

Language :
English
ISSN :
03639762 and 15360229
Volume :
41
Issue :
3
Database :
Supplemental Index
Journal :
Clinical Nuclear Medicine
Publication Type :
Periodical
Accession number :
ejs48437389
Full Text :
https://doi.org/10.1097/RLU.0000000000001083